magnesium chloride 535 MG Delayed Release Oral Tablet [Mag 64]
Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
magnesium chloride 535 MG Delayed Release Oral Tablet [Mag 64]
535 MG · Delayed Release Oral Tablet · oral
A form of magnesium →
magnesium chloride 535 MG Delayed Release Oral Tablet [Mag 64]. Strength, form, class, interactions & more.
![magnesium chloride 535 MG Delayed Release Oral Tablet [Mag 64]](https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4467134e-018f-2ad6-e063-6294a90a42bb&name=esomeprazole-ifc-14s.jpg)
Active ingredient
Drug interactions
The label outlines several drug interactions with esomeprazole, including those with antiretrovirals, warfarin, methotrexate, and others.
- majorrilpivirine — Contraindicated due to reduced antiviral effect and potential for drug resistance.
- majorwarfarin — Increased INR and prothrombin time, leading to abnormal bleeding and potential death.
- moderatemethotrexate — Elevated and prolonged serum concentrations of methotrexate, possibly leading to toxicities.
- majorclopidogrel — Reduced plasma concentrations of the active metabolite of clopidogrel and reduced platelet inhibition.
- moderatecitalopram — Increased exposure leading to an increased risk of QT prolongation.
- moderatecilostazol — Increased exposure of cilostazol and its active metabolite.
- moderatedigoxin — Potential for increased exposure of digoxin.
- moderatemycophenolate mofetil — Reduced exposure to the active metabolite, mycophenolic acid, possibly affecting organ rejection.
- moderatetacrolimus — Potentially increased exposure of tacrolimus, especially in certain metabolizers.
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication